HMG-CoA reductase inhibitors, commonly known as statins, are some of the most widely prescribed medications worldwide and have been shown to be effective at lowering cholesterol in numerous long-term prospective trials, yet there are significant limitations to their use. First, patients receiving statin therapy have relatively low levels of medication adherence compared with other drug classes. Next, numerous statin formulations are available, each with its own unique safety and efficacy profile, and it may be unclear to prescribers which treatment is optimal for their patients. Finally, statins have class-wide side effects of myopathy and rhabdomyolysis that have resulted in a product recall and dosage limitations. Recent evidence suggests that two genomic markers, KIF6 and SLCO1B1, may inform the therapy choice of patients initiating statins. Given the prevalence of statin usage, their potential health advantages and their overall cost to the healthcare system, there could be significant clinical benefit from creating personalized treatment regimens. Ultimately, if this approach is effective it may encourage higher adoption of generic statins when appropriate, promote adherence, lower rates of myopathy, and overall achieve higher value cardiovascular care. This paper will review the evidence for personalized prescribing of statins via KIF6 and SLCO1B1 and consider some of the implications for testing these markers as part of routine clinical care.
References
[1]
NHLBI Fact Book. Available online: http://www.nhlbi.nih.gov/about/factpdf.htm (accessed on 1 June 2012).
[2]
Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; et al. Heart disease and stroke statistics—2012 update: A report from the american heart association. Circulation 2012, 125, e2–e220, doi:10.1161/CIR.0b013e31823ac046.
[3]
IMS Institute for Healthcare Informatics. The use of medicines in the united states: Review of 2011. Available online: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf (accessed on 1, August, 2012).
[4]
Staffa, J.A.; Chang, J.; Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 2002, 346, 539–540.
[5]
Egan, A.; Colman, E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N. Engl. J. Med. 2011, 365, 285–287, doi:10.1056/NEJMp1106689.
[6]
Andrade, S.E.; Walker, A.M.; Gottlieb, L.K.; Hollenberg, N.K.; Testa, M.A.; Saperia, G.M.; Platt, R. Discontinuation of antihyperlipidemic drugs—Do rates reported in clinical trials reflect rates in primary care settings? N. Engl. J. Med. 1995, 332, 1125–1131.
[7]
Simons, L.A.; Levis, G.; Simons, J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med. J. Aust. 1996, 164, 208–211.
[8]
Avorn, J.; Monette, J.; Lacour, A.; Bohn, R.L.; Monane, M.; Mogun, H.; LeLorier, J. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998, 279, 1458–1462, doi:10.1001/jama.279.18.1458.
[9]
Flack, J.M.; Novikov, S.V.; Ferrario, C.M. Benefits of adherence to anti-hypertensive drug therapy. Eur. Heart J. 1996, 17 Suppl. A, 16–20.
[10]
Haynes, R.B.; McKibbon, K.A.; Kanani, R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996, 348, 383–386.
[11]
Osterberg, L.; Blaschke, T. Adherence to medication. N. Engl. J. Med. 2005, 353, 487–497, doi:10.1056/NEJMra050100.
[12]
McCarthy, R. The price you pay for the drug not taken. Bus. Health 1998, 16, 27-28, 30, 32-33.
[13]
Bosworth, H.B.; Granger, B.B.; Mendys, P.; Brindis, R.; Burkholder, R.; Czajkowski, S.M.; Daniel, J.G.; Ekman, I.; Ho, M.; Johnson, M.; et al. Medication adherence: A call for action. Am. Heart J. 2011, 162, 412–424.
[14]
Berg, J.S.; Dischler, J.; Wagner, D.J.; Raia, J.J.; Palmer-Shevlin, N. Medication compliance: A healthcare problem. Ann. Pharmacother. 1993, 27, S1–S24.
[15]
Levy, G.; Zamacona, M.K.; Jusko, W.J. Developing compliance instructions for drug labeling. Clin. Pharmacol. Ther. 2000, 68, 586–591, doi:10.1067/mcp.2000.110976.
[16]
McDonnell, P.J.; Jacobs, M.R. Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. 2002, 36, 1331–1336.
[17]
Cherry, S.B.; Benner, J.S.; Hussein, M.A.; Tang, S.S.; Nichol, M.B. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009, 12, 489–497, doi:10.1111/j.1524-4733.2008.00447.x.
[18]
Roebuck, M.C.; Liberman, J.N.; Gemmill-Toyama, M.; Brennan, T.A. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff. (Millwood) 2011, 30, 91–99, doi:10.1377/hlthaff.2009.1087.
[19]
Jackevicius, C.A.; Mamdani, M.; Tu, J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288, 462–467, doi:10.1001/jama.288.4.462.
[20]
McNicholl, I.R. Strategies to enhance adherence, reduce costs, and improve patient quality of life. J. Manag. Care Pharm. 2008, 14, S12–S16.
[21]
Marteau, T.; Senior, V.; Humphries, S.E.; Bobrow, M.; Cranston, T.; Crook, M.A.; Day, L.; Fernandez, M.; Horne, R.; Iversen, A.; et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. Am. J. Med. Genet. A 2004, 128A, 285–293, doi:10.1002/ajmg.a.30102.
[22]
Grant, R.W.; Hivert, M.; Pandiscio, J.C.; Florez, J.C.; Nathan, D.M.; Meigs, J.B. The clinical application of genetic testing in type 2 diabetes: A patient and physician survey. Diabetologia 2009, 52, 2299–2305, doi:10.1007/s00125-009-1512-7.
[23]
Umans-Eckenhausen, M.A.; Defesche, J.C.; van Dam, M.J.; Kastelein, J.J. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch. Intern. Med. 2003, 163, 65–68, doi:10.1001/archinte.163.1.65.
[24]
Narod, S.A. Compliance with tamoxifen in women with breast cancer and a brca1 or brca2 mutation. J. Clin. Oncol. 2010, 28, e698–e699, doi:10.1200/JCO.2010.31.5770.
[25]
Heshka, J.T.; Palleschi, C.; Howley, H.; Wilson, B.; Wells, P.S. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet. Med. 2008, 10, 19–32, doi:10.1097/GIM.0b013e31815f524f.
[26]
Donnelly, L.A.; Doney, A.S.; Tavendale, R.; Lang, C.C.; Pearson, E.R.; Colhoun, H.M.; McCarthy, M.I.; Hattersley, A.T.; Morris, A.D.; Palmer, C.N. Common nonsynonymous substitutions in slco1b1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A go-darts study. Clin. Pharmacol. Ther. 2011, 89, 210–216, doi:10.1038/clpt.2010.255.
[27]
Charland, S.L.; Agatep, B.C.; Epstein, R.S.; Frueh, F.W.; Herrera, V.; Devlin, J.; Superko, H.; Stanek, E.J. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the additional kif6 risk offers better adherence to statins (akrobats) trial. J. Am. Coll. Cardiol. 2012, 59.
Li, Y.; Iakoubova, O.A.; Shiffman, D.; Devlin, J.J.; Forrester, J.S.; Superko, H.R. Kif6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Am. J. Cardiol. 2010, 106, 994–998, doi:10.1016/j.amjcard.2010.05.033.
[30]
Ference, B.A.; Yoo, W.; Flack, J.M.; Clarke, M. A common kif6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: Two meta-analyses and a meta-regression analysis. PLoS One 2011, 6, e28834.
[31]
Self-efficacy in the context of health psychology is defined as a patient’s sense of their capability to improve their health outcomes via behavior change.
[32]
Bloss, C.S.; Madlensky, L.; Schork, N.J.; Topol, E.J. Genomic information as a behavioral health intervention: Can it work? Pers. Med. 2011, 8, 659–667, doi:10.2217/pme.11.73.
[33]
Morrison, A.C.; Bare, L.A.; Chambless, L.E.; Ellis, S.G.; Malloy, M.; Kane, J.P.; Pankow, J.S.; Devlin, J.J.; Willerson, J.T.; Boerwinkle, E. Prediction of coronary heart disease risk using a genetic risk score: The atherosclerosis risk in communities study. Am. J. Epidemiol. 2007, 166, 28–35, doi:10.1093/aje/kwm060.
[34]
Bare, L.A.; Morrison, A.C.; Rowland, C.M.; Shiffman, D.; Luke, M.M.; Iakoubova, O.A.; Kane, J.P.; Malloy, M.J.; Ellis, S.G.; Pankow, J.S.; et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet. Med. 2007, 9, 682–689, doi:10.1097/GIM.0b013e318156fb62.
[35]
Shiffman, D.; Sabatine, M.S.; Louie, J.Z.; Kirchgessner, T.G.; Iakoubova, O.A.; Campos, H.; Devlin, J.J.; Sacks, F.M. Effect of pravastatin therapy on coronary events in carriers of the kif6 719arg allele from the cholesterol and recurrent events trial. Am. J. Cardiol. 2010, 105, 1300–1305, doi:10.1016/j.amjcard.2009.12.049.
[36]
Iakoubova, O.A.; Robertson, M.; Tong, C.H.; Rowland, C.M.; Catanese, J.J.; Blauw, G.J.; Jukema, J.W.; Murphy, M.B.; Devlin, J.J.; Ford, I.; et al. Kif6 trp719arg polymorphism and the effect of statin therapy in elderly patients: Results from the prosper study. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17, 455–461, doi:10.1097/HJR.0b013e328336a0dd.
[37]
Iakoubova, O.A.; Sabatine, M.S.; Rowland, C.M.; Tong, C.H.; Catanese, J.J.; Ranade, K.; Simonsen, K.L.; Kirchgessner, T.G.; Cannon, C.P.; Devlin, J.J.; et al. Polymorphism in kif6 gene and benefit from statins after acute coronary syndromes: Results from the prove it-timi 22 study. J. Am. Coll. Cardiol. 2008, 51, 449–455.
[38]
Shiffman, D.; Chasman, D.I.; Zee, R.Y.; Iakoubova, O.A.; Louie, J.Z.; Devlin, J.J.; Ridker, P.M. A kinesin family member 6 variant is associated with coronary heart disease in the women’s health study. J. Am. Coll. Cardiol. 2008, 51, 444–448, doi:10.1016/j.jacc.2007.09.044.
[39]
Iakoubova, O.A.; Tong, C.H.; Rowland, C.M.; Kirchgessner, T.G.; Young, B.A.; Arellano, A.R.; Shiffman, D.; Sabatine, M.S.; Campos, H.; Packard, C.J.; et al. Association of the trp719arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The care and woscops trials. J. Am. Coll. Cardiol. 2008, 51, 435–443, doi:10.1016/j.jacc.2007.05.057.
[40]
Allingham-Hawkins, D.; Lea, A.; Levine, S. Kif6 p.Trp719arg testing to assess risk of coronary artery disease and/or statin response. PLoS Curr. 2010, 2, RN1191, doi:10.1371/currents.RRN1191.
[41]
Topol, E.J.; Damani, S.B. The kif6 collapse. J. Am. Coll. Cardiol. 2010, 56, 1564–1566.
[42]
Hopewell, J.C.; Parish, S.; Clarke, R.; Armitage, J.; Bowman, L.; Hager, J.; Lathrop, M.; Collins, R. No impact of kif6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J. Am. Coll. Cardiol. 2011, 57, 2000–2007.
[43]
Ridker, P.M.; MacFadyen, J.G.; Glynn, R.J.; Chasman, D.I. Kinesin-like protein 6 (kif6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ. Cardiovasc. Genet. 2011, 4, 312–317, doi:10.1161/CIRCGENETICS.110.959353.
[44]
Arsenault, B.J.; Boekholdt, S.M.; Hovingh, G.K.; Hyde, C.L.; DeMicco, D.A.; Chatterjee, A.; Barter, P.; Deedwania, P.; Waters, D.D.; LaRosa, J.C.; et al. The 719arg variant of kif6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ. Cardiovasc. Genet. 2012, 5, 51–57, doi:10.1161/CIRCGENETICS.111.960252.
[45]
Assimes, T.L.; Holm, H.; Kathiresan, S. Lack of association between the trp719arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J. Am. Coll. Cardiol. 2010, 56, 1552–1563.
[46]
Proportion of days covered (PDC) is a measurement used to quantify a patient’s level of medication adherence. It is defined as a ratio of the number of days of medication that a patient had available to them over the complete coverage period. For example if a patient was given a 60 day statin prescription but only filled their script for one of those months, they would have a PDC of 0.5.
[47]
Ghatak, A.; Faheem, O.; Thompson, P.D. The genetics of statin-induced myopathy. Atherosclerosis 2010, 210, 337–343, doi:10.1016/j.atherosclerosis.2009.11.033.
[48]
US Food and Drug Administration. FDA drug safety communication: Ongoing safety review of high-dose zocor (simvastatin) and increased risk of muscle injury. Available online: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm (accessed on 16 June 2011).
[49]
Josan, K.; Majumdar, S.R.; McAlister, F.A. The efficacy and safety of intensive statin therapy: A meta-analysis of randomized trials. CMAJ 2008, 178, 576–584.
[50]
Cohen, J.D.; Brinton, E.A.; Ito, M.K.; Jacobson, T.A. Understanding statin use in america and gaps in patient education (usage): An internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 2012, 6, 208–215, doi:10.1016/j.jacl.2012.03.003.
[51]
Bruckert, E.; Hayem, G.; Dejager, S.; Yau, C.; Begaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—The primo study. Cardiovasc. Drugs Ther. 2005, 19, 403–414, doi:10.1007/s10557-005-5686-z.
[52]
Kiortsis, D.N.; Giral, P.; Bruckert, E.; Turpin, G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J. Clin. Pharm. Ther. 2000, 25, 445–451, doi:10.1046/j.1365-2710.2000.00315.x.
[53]
Bruckert, E.; Simonetta, C.; Giral, P. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3,845 patients with hyperlipidemia. Creole study team. J. Clin. Epidemiol. 1999, 52, 589–594, doi:10.1016/S0895-4356(99)00019-0.
[54]
Mann, D.M.; Woodward, M.; Muntner, P.; Falzon, L.; Kronish, I. Predictors of nonadherence to statins: A systematic review and meta-analysis. Ann. Pharmacother. 2010, 44, 1410–1421, doi:10.1345/aph.1P150.
[55]
Mann, D.M.; Allegrante, J.P.; Natarajan, S.; Halm, E.A.; Charlson, M. Predictors of adherence to statins for primary prevention. Cardiovasc. Drugs Ther. 2007, 21, 311–316, doi:10.1007/s10557-007-6040-4.
[56]
Brown, M.T.; Bussell, J.K. Medication adherence: Who cares? Mayo Clin. Proc. 2011, 86, 304–314, doi:10.4065/mcp.2010.0575.
[57]
Pasanen, M.K.; Neuvonen, M.; Neuvonen, P.J.; Niemi, M. Slco1b1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 2006, 16, 873–879, doi:10.1097/01.fpc.0000230416.82349.90.
[58]
Voora, D.; Shah, S.H.; Spasojevic, I.; Ali, S.; Reed, C.R.; Salisbury, B.A.; Ginsburg, G.S. The slco1b1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 2009, 54, 1609–1616, doi:10.1016/j.jacc.2009.04.053.
[59]
Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. Slco1b1 variants and statin-induced myopathy—A genomewide study. N. Engl. J. Med. 2008, 359, 789–799, doi:10.1056/NEJMoa0801936.
[60]
Oshiro, C.; Mangravite, L.; Klein, T.; Altman, R. Pharmgkb very important pharmacogene: Slco1b1. Pharmacogenet. Genomics 2010, 20, 211–216.
[61]
Tirona, R.G.; Leake, B.F.; Merino, G.; Kim, R.B. Polymorphisms in oatp-c: Identification of multiple allelic variants associated with altered transport activity among european- and african-americans. J. Biol. Chem. 2001, 276, 35669–35675.
[62]
Mwinyi, J.; Kopke, K.; Schaefer, M.; Roots, I.; Gerloff, T. Comparison of slco1b1 sequence variability among german, turkish, and african populations. Eur. J. Clin. Pharmacol. 2008, 64, 257–266.
[63]
Nozawa, T.; Nakajima, M.; Tamai, I.; Noda, K.; Nezu, J.; Sai, Y.; Tsuji, A.; Yokoi, T. Genetic polymorphisms of human organic anion transporters oatp-c (slc21a6) and oatp-b (slc21a9): Allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 2002, 302, 804–813, doi:10.1124/jpet.302.2.804.
[64]
Nishizato, Y.; Ieiri, I.; Suzuki, H.; Kimura, M.; Kawabata, K.; Hirota, T.; Takane, H.; Irie, S.; Kusuhara, H.; Urasaki, Y.; et al. Polymorphisms of oatp-c (slc21a6) and oat3 (slc22a8) genes: Consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003, 73, 554–565, doi:10.1016/S0009-9236(03)00060-2.
[65]
Ho, W.F.; Koo, S.H.; Yee, J.Y.; Lee, E.J. Genetic variations of the slco1b1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab. Pharmacokinet. 2008, 23, 476–482, doi:10.2133/dmpk.23.476.
[66]
Couvert, P.; Giral, P.; Dejager, S.; Gu, J.; Huby, T.; Chapman, M.J.; Bruckert, E.; Carrie, A. Association between a frequent allele of the gene encoding oatp1b1 and enhanced ldl-lowering response to fluvastatin therapy. Pharmacogenomics 2008, 9, 1217–1227.
[67]
Pasanen, M.K.; Backman, J.T.; Neuvonen, P.J.; Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1b1 slco1b1 gene in a finnish population. Eur. J. Clin. Pharmacol. 2006, 62, 409–415, doi:10.1007/s00228-006-0123-1.
[68]
Area under the curve (AUC) is measure commonly used in pharmacokinetics and is defined as the area under the plot of plasma concentration of drug against time after the initial drug administration. AUC may be used as a proxy measure of systemic exposure to a drug over a given time window.
[69]
Neuvonen, P.J.; Niemi, M.; Backman, J.T. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin. Pharmacol. Ther. 2006, 80, 565–581, doi:10.1016/j.clpt.2006.09.003.
[70]
Marciante, K.D.; Durda, J.P.; Heckbert, S.R.; Lumley, T.; Rice, K.; McKnight, B.; Totah, R.A.; Tamraz, B.; Kroetz, D.L.; Fukushima, H.; et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 2011, 21, 280–288, doi:10.1097/FPC.0b013e328343dd7d.
[71]
Upper limit of normal (ULN) is the upper threshold value of a normal range for a defined laboratory measure. >3×ULN would be a value that is greater than threefold higher than the upper limit of a normal range.
[72]
Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 2010, 87, 130–133, doi:10.1038/clpt.2009.197.
[73]
Wilke, R.A.; Ramsey, L.B.; Johnson, S.G.; Maxwell, W.D.; McLeod, H.L.; Voora, D.; Krauss, R.M.; Roden, D.M.; Feng, Q.; Cooper-DeHoff, R.M.; et al. The clinical pharmacogenomics implementationconsortium: Cpic guideline for slco1b1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 2012, 92, 112–117, doi:10.1038/clpt.2012.57.
